Literature DB >> 28678780

Cancer: Keeping it real to kill glioblastoma.

Paul A Northcott1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28678780     DOI： 10.1038/nature23095

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  15 in total

1.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

Review 2.  Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date.

Authors:  Jayson I L Bastien; Katharine A McNeill; Howard A Fine
Journal:  Cancer       Date:  2014-09-23       Impact factor: 6.860

Review 3.  Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.

Authors:  Aristeidis Chaidos; Valentina Caputo; Anastasios Karadimitris
Journal:  Ther Adv Hematol       Date:  2015-06

Review 4.  Targeting the cancer epigenome for therapy.

Authors:  Peter A Jones; Jean-Pierre J Issa; Stephen Baylin
Journal:  Nat Rev Genet       Date:  2016-09-15       Impact factor: 53.242

Review 5.  Epigenetic modulators, modifiers and mediators in cancer aetiology and progression.

Authors:  Andrew P Feinberg; Michael A Koldobskiy; Anita Göndör
Journal:  Nat Rev Genet       Date:  2016-03-14       Impact factor: 53.242

6.  Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release.

Authors:  Wen Liu; Qi Ma; Kaki Wong; Wenbo Li; Kenny Ohgi; Jie Zhang; Aneel Aggarwal; Michael G Rosenfeld
Journal:  Cell       Date:  2013-12-19       Impact factor: 41.582

7.  Inhibition of BET bromodomain targets genetically diverse glioblastoma.

Authors:  Zhixiang Cheng; Yuanying Gong; Yufang Ma; Kaihua Lu; Xiang Lu; Larry A Pierce; Reid C Thompson; Susanne Muller; Stefan Knapp; Jialiang Wang
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

8.  OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.

Authors:  Caroline Berenguer-Daizé; Lucile Astorgues-Xerri; Elodie Odore; Mylène Cayol; Esteban Cvitkovic; Kay Noel; Mohamed Bekradda; Sarah MacKenzie; Keyvan Rezai; François Lokiec; Maria E Riveiro; L'Houcine Ouafik
Journal:  Int J Cancer       Date:  2016-07-30       Impact factor: 7.396

Review 9.  Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors.

Authors:  Elizabeth Wadhwa; Theodore Nicolaides
Journal:  Cureus       Date:  2016-05-21

10.  Transcription elongation factors represent in vivo cancer dependencies in glioblastoma.

Authors:  Tyler E Miller; Brian B Liau; Lisa C Wallace; Andrew R Morton; Qi Xie; Deobrat Dixit; Daniel C Factor; Leo J Y Kim; James J Morrow; Qiulian Wu; Stephen C Mack; Christopher G Hubert; Shawn M Gillespie; William A Flavahan; Thomas Hoffmann; Rohit Thummalapalli; Michael T Hemann; Patrick J Paddison; Craig M Horbinski; Johannes Zuber; Peter C Scacheri; Bradley E Bernstein; Paul J Tesar; Jeremy N Rich
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962
View more
  4 in total

1.  Hsp90 inhibitor NMS-E973 exerts the anticancer effect against glioblastoma via induction of PUMA-mediated apoptosis.

Authors:  Libo Sun; Shoujun Yang; Guonan Chi; Xingyi Jin
Journal:  Onco Targets Ther       Date:  2018-03-20       Impact factor: 4.147

2.  MicroRNA-1225-5p behaves as a tumor suppressor in human glioblastoma via targeting of IRS1.

Authors:  Dongyuan Li; Guonan Chi; Zhuo Chen; Xingyi Jin
Journal:  Onco Targets Ther       Date:  2018-09-28       Impact factor: 4.147

Review 3.  Review: Synthetic scaffolds to control the biochemical, mechanical, and geometrical environment of stem cell-derived brain organoids.

Authors:  Mariana Oksdath; Sally L Perrin; Cedric Bardy; Emily F Hilder; Cole A DeForest; R Dario Arrua; Guillermo A Gomez
Journal:  APL Bioeng       Date:  2018-11-15

Review 4.  Jumonji domain-containing protein 6 protein and its role in cancer.

Authors:  Jing Yang; Siyuan Chen; Yanfei Yang; Xuelei Ma; Bin Shao; Shengyong Yang; Yuquan Wei; Xiawei Wei
Journal:  Cell Prolif       Date:  2020-01-21       Impact factor: 6.831
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.